Taken together, these data demonstrate increased GPNMB and CD44 gene expression in the substantia nigra of PD patients and in animal models of PD, with increased CD44 protein levels in GFAP-positive astrocytes following MPTP treatment. Here, GFAP is linked to Parkinson disease.